Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
暂无分享,去创建一个
K. Hayashi | K. Kawakami | G. Nakajima | T. Araida | R. Okuyama | H. Kuramochi | S. Kameoka | K. Yoshimatsu | M. Itabashi | H. Yokomizo | M. Ando | M. Hamano | E. Hirai | Ryuji Okuyama